Healthcare Capital & Connections Summit


September 11 - 13, 2018
Shanghai, China

Register Now
English | Chinese (中文)


2018 Summit Details


Summit speakers and attendee information will be updated regularly to help you plan your 2018 Summit schedule.

  1. Agenda

    2018 SUMMIT AGENDA

    We continue to add finalize sessions and speakers. Visit this webpage for updates.

    Day One: Tuesday, September, 11, 2018

     

    Day Three: Thursday, September 13, 2018

    13:00 - 17:00 Site Visit   9:00 - 9:15 Welcome and Opening Remarks

    18:30 - 20:00 

    Welcome Reception
      9:15 - 10:00 Lessons in Cross Border M&A and Financing - What you Need to Know From Those Who Have Walked the Path

    Day Two: Wednesday, September 12, 2018

      10:00 - 10:30 Break

    9:00 - 9:15

    Welcome and Opening Remarks

      10:30 - 11:15 Politics and Global Trade - Implications for Cross-border Deal Making and Investment
    9:15 - 10:00 China Innovation - Is the Era of "Me-Too" Over?   11:15 - 12:15 Impact of Changing CNDA Policy on Cross Border Deal Making
    10:15 - 11:00 The Hong Kong Exchange - Implications for the Global Life Sciences Innovation Ecosystem   12:15 - 13:15 Lunch
    11:00 - 11:30 What Western Therapeutic Markets Will Translate to China...and What Won't?   13:30 - 16:30 1 on 1 Meetings & Company Presentations
    11:30 - 12:15 The US Perspective - Key Priorities for US Executivies in China      
    12:30 - 13:30 Lunch      
    13:30 - 16:30 Company Presentations and 1 on 1 Meetings      
    17:30 - 18:30 Cocktail Reception      
    18:30 - 21:00 Dinner hosted by SPD Silicon Valley Bank      
  2. Speakers

    2018 SUMMIT SPEAKERS

    Mark Bach
    Vice President and Head of Asia Pacific Medical Sciences, China Innovation Leader
    Johnson & Johnson

    As head of Asia Pacific Medical Sciences since 2012, Mark Bach leads an Asia Pacific team of over 1,400 science professionals in Drug Discovery, Clinical Development, and Medical Affairs dedicated to delivering transformational healthcare innovation.

    In September 2014, Mark took on the additional responsibility of leading a fast-growing Janssen R&D and Medical Affairs team in China, one of the Company’s four global hubs for drug discovery and development. In his two roles, Mark has focused on building organizational capabilities and eliminating ‘drug lag’ to bring important new medicines to patients in need across the region.

    Mark joined Janssen in 2010 as Vice President and Head of the Japan Medical Organization, where he led the team responsible for scientific and medical activity, including R&D, regulatory, drug safety, scientific affairs, healthcare policy, market access, and pricing. During Mark’s tenure, he led major change initiatives that drove substantial increases in productivity and a one-team culture around a common vision and purpose. Mark joined the pharmaceutical industry in 1993 with Merck & Co., where he held positions of increasing responsibility in global, regional and Japan-based roles over 16 years, including the roles of Deputy Head of Clinical Development in Japan and Head of Global Clinical Research Operations.

    Mark received his Ph.D. in Pathology from the University of Chicago and his medical degree from the Baylor College of Medicine, where he also served his residency in pediatrics. He was trained as a Pediatric Endocrinologist at the U.S. National Institutes of Health.

    Andy Clayton
    Managing Director & Head of Asia Healthcare Investment Banking
    Piper Jaffray

    Andy Clayton is a managing director and head of Asia healthcare investment banking. He has more than 15 years of healthcare investment banking experience. Clayton has successfully completed more than 40 transactions across a broad range of products, including debt, equity, and mergers and acquisitions.

    Prior to joining Piper Jaffray, Clayton was a senior calling officer at Jefferies, where he was dedicated to serving Asian healthcare clients. Previously, he was a director in the UBS Investment Bank healthcare group, where he spent five years serving clients in both the U.S. and Asian markets. Before joining UBS in 2004, Clayton worked as a director of corporate development at SunGard Data Systems, where he focused on executing M&A transactions. Clayton received a Master of Business Administration degree from The University of Chicago Booth School of Business and a bachelor’s degree from Williams College.

    Dan Croteau
    CEO 
    Surgicial Specialties Corporation

    In October 2017 Dan Croteau joined Surgical Specialties Corporation as its CEO. Surgical Specialties Corporation is a private equity backed company that specializes in high performance wound closure products and surgical knives.

    From January, 2011 to March, 2017 Dan served as the CEO of Vention Medical, a private equity backed provider of medical device design, engineering, component manufacturing and finished device assembly services for single use interventional and surgical medical devices. The company was sold in two transactions to Nordson Corporation and MedPlast Corporation in March 2017.

    Previously Dan served as the President of FlexMedical, the medical division of Flex (Nasdaq FLEX), for almost 5 years, building a global manufacturing and supply chain division focused on disposable medical devices, diagnostic instrumentation, and drug delivery devices.

    Prior to that, Dan served in a variety of executive roles in the medical device industry; most notably as Executive Vice President and General Manager of Accellent (now part of Integer/Greatbach); and as a Senior Vice President of Medsource Technologies, which was merged in 2005 with UTI Corporation to form Accellent. Prior to entering the medical device industry in 1999, Dan spent the majority of his career in various roles at GE and working as a consultant for Booz & Company in Sydney Australia.

    Dan has a Bachelor of Science degree in Mechanical Engineering from the University of Vermont, and a Master of Business Administration from Harvard Business School.

    Dr. Jasmine Cui
    Co-founder, President & CEO of
    Beijing InnoCare Pharma Tech

    Dr. Jasmine Cui is the co-founder, President & CEO of Beijing InnoCare Pharma Tech. Ltd. (InnoCare). Prior to founding InnoCare, Dr. Cui was the General Manager of BioDuro (2011-2015). Her area of responsibility included BioDuro’s overall scientific and operational management, as well as business & resource management. Before BioDuro, Dr. Cui worked at Merck Research Laboratories for 14 years serving as Director of Cardiovascular Diseases where she provided project leadership for delivering >10 drug candidates. She also served as the Chair of Early Development Team for development of drug candidate from preclinical to clinical phase 2a for POC in humans. She also headed the hypertension exploratory biomarker for identifying and developing preclinical and translatable biomarkers in cardiovascular diseases.

    Dr. Cui received her Ph.D. in biology from Purdue University and completed her postdoctoral fellowship at Howard Hughes Medical Institute affiliated with the University of Michigan. Dr. Cui was the 17th SAPA President with the honor to be the first female President in the history of SAPA. Currently, Dr. Cui is the president of SAPA China.

    William (Skip) Fisher
    Partner
    DLA Piper

    Skip has practiced intellectual property (IP) law in the U.S., China and internationally for over 20 years. Skip’s practice focuses on IP asset management and strategy, licensing and technology transfer, and IP enforcement and litigation. Skip works in all areas of intellectual property with an emphasis on patents and trade secrets.

    Skip helps companies establish and implement strategies for procuring, commercializing and enforcing their IP rights, and for minimizing risk to their IP assets, in China, the U.S. and globally. He advises companies on Chinese, U.S. and international IP laws; conducts all aspects of IP due diligence, including assessing validity and infringement risk; negotiates and drafts IP and technology licenses, collaboration and co-development contracts and other commercial agreements; and represents companies in high-stakes IP litigation and enforcement actions.

    Over the years, Skip has worked in a variety of industry sectors, including biotechnology, chemical, medical devices, pharmaceutical, mechanical and industrial products, computer networks, electronics, aerospace and automotive. Most recently, he has helped a Chinese pharmaceutical company conclude several cross-border drug in-licensing transactions, has conducted IP due diligence and negotiated license agreements for a Chinese private equity firm in connection with its investments in two technology start-up companies, and has advised one of the world’s largest medical device/technology companies on patent and other IP issues in connection with its potential acquisition of a Chinese company and potential licensing of technology/IP from another Chinese company.

    Kewen Jin, M.D.
    Managing Partner
    Serica Capital

    Kewen Jin is a serial entrepreneur and investor in the China life science industry. He is currently Managing Partner / co-founder of Serica Capital, a China-based medtech fund. Over the last 15 years, Kewen has co-founded and served as CEO / key executives of several companies in CRO, drug development , and medical device, most recently co-founder / CEO of SyMap, a leading device company in the Renal Denervation for Hypertension area.

    He has served as an advisor to numerous pharmaceutical / medtech companies, consulting / investment firms, notably Gates Foundation and Advent, the global PE. He advised two leading life science parks in China, Shanghai Zhangjiang and Suzhou Biobay, in developing and implementing strategic plan. He was the founding Chair of the Shanghai CRO Association.

    He was a marketing and international operation executive with Wyeth from 1993 to 2000, in the U.S. and China. He was the Chairman of Board of The BayHelix Group from 2014 to 2017, an organization of Chinese life sciences business leaders in China and the U.S. He was trained in medicine (Shanghai Jiaotong University School of Medicine), molecular biology (Rockefeller), and finance (Columbia).

    Portia Ku
    Partner
    O'Melveny & Myers LLP

    Portia Ku is an accomplished corporate transactional lawyer who specializes in capital markets, mergers and acquisitions, venture capital and private equity financings. Portia’s clients include public and private companies that span a variety of industries, including the technology, life sciences, healthcare, and financial services sectors. Portia has successfully completed a myriad of deals on behalf of her clients. She applies her expansive technical experience, strategic execution, and dedication to guide clients through highly complex transactions while ultimately helping them achieve their corporate goals.

    Jacob Parker
    Vice President, China Operations
    US-China Business Council

    Jacob Parker is the vice president of China operations at the US-China Business Council. In this role he manages USCBC’s two offices in Beijing and Shanghai and oversees the development and execution of China-based research, reporting, and programming on trends of importance to US businesses operating in China. He has worked on a variety of international public and private projects throughout his career. Before joining USCBC, Jacob worked as a program manager at Philips Healthcare where he oversaw implementation of ExIm Bank, Nordic Investment Bank, and Ashra Bank international government loan projects for developing medical infrastructure in China. Prior to that, as the director of operations of the USA Pavilion Shanghai Expo 2010, Jacob was responsible for the set-up, maintenance, and general operation of the pavilion, and for sharing American culture and values with the more than 7 million visitors during the six months of operation.

    David M. Sabow
    Group Head of Life Sciences, Client Funds and Bank Products
    Silicon Valley Bank

    David Sabow is the head of Silicon Valley Bank’s life science and healthcare practice, client funds and products. He manages deal teams across the country, drives the sales and marketing strategy, assists with the structuring of complex credits and presents regularly at global industry conferences. With more than 15 years of life science and healthcare finance experience, David’s background includes structuring senior and subordinated debt, IPOs, follow-on offerings, mergers & acquisitions and strategic advisory roles across the sector.

    Prior to joining Silicon Valley Bank, David spent nine years in the life science investment banking practice at Canaccord Genuity, with responsibility for both domestic and international deals across the life science and healthcare spectrum, specializing in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. Before Canaccord, David worked as a relationship manager with U.S. Bank.

    David graduated with distinction from Santa Clara University, and recently completed the executive program at Dartmouth’s Tuck School of Business, focusing on Leadership and Strategic Impact. He lives in Needham, Massachusetts with his wife and three children.

    Greg B. Scott
    Founder and Chairman
    ChinaBio® Group

    Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on investment and partnering, including the ChinaBio® Partnering Forum which draws over 1000 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He is considered a leading expert on China’s life science industry, and is frequently quoted in the media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, etc. Headquartered in Shanghai, ChinaBio® has staff in San Diego, Palo Alto, and Basel, Switzerland.

    John Wang
    Managing Director
    CVCapital

    John Wang has 22 years Healthcare related experience. He completed 30 M&A and private placement transactions in healthcare related sectors, including Bio-pharmaceutical, Med-Tech, Healthcare Services, etc. He developed close relationship with many large and medium-sized healthcare companies, and successfully closed seven co-investment projects. He was a EMBA, from Washington University in St. Louis and Fudan University and double degree in Industrial and Electrical Automation and Management, Jiangsu Science and Technology University.

    Jonathan Wang
    SVP, Head of Business Development
    Zai Lab

    Jonathan Wang is our head of business development since 2014. Prior to joining Zai Lab, Mr. Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to 2011, Mr. Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr. Wang also gained financial transactional experience at Goldman Sachs Investment Banking. Mr. Wang received a master of business administration in healthcare management from Wharton Business School.

    Chen Yu
    Managing Partner
    Vivo Capital

    Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Dr. Yu also served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which was acquired by Nichi-Iko for $763 M in 2016. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Kala (KALA), Nabriva (NBRV), Rempex (Acquired by MDCO), Outpost Medicine(US), Sentre Heart (US), Jian Rui Bao (China), and GMT Medical (China). Other representative investments include Zai Labs, Trauson (acquired by Stryker for $764 MM), Durata (acquired by Actavis for $675M), RiverVision (acquired by Horizon), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX).

    Dr. Yu is also active in the community, including serving on the California Leadership Council for the Nature Conservancy and the Fund Development Committee for the California chapter of the Alzheimer’s Association. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.

    Dr. Bing Yuan
    Chief Business Officer
    CStone Pharmaceuticals

    Dr. Bing Yuan is currently Chief Business Officer at CStone Pharmaceuticals, responsible for business and commercial related functions, including BD&L, corporate strategy, public relations, government affairs and new product launch. He is a seasoned business executive with extensive experience in business development and marketing strategy, made significant contributions to 9 global oncology brands. Before joining CStone, he was Executive Director and Global Lead of Oncology BD at Merck (MSD). He focused on expanding Merck's leadership position in cancer immunotherapy, and successfully achieved 34 M&A, licensing and Keytruda collaboration deals. Before Merck, he was Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, responsible for Glivecand Afinitor brand life cycle strategy. He played a key role in global launch of Zykadia in ALK+ lung cancer and was a core deal team member that in-licensed Jakavi from Incyte. He was three-time Novartis Oncology President Award recipient. He also served as Global Oncology Marketing Lead at Eisai in the past, managing entire oncology portfolio. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, a MBA from Cornell University and B.S. of Biochemistry from Nanjing University.

    William Zarit
    Senior Counselor
    The Cohen Group

    The Honorable William Zarit advises major Chinese companies on how to navigate the US investment market, and helps US multinationals working in the Chinese commercial environment. He also serves as Chairman of the Board for the American Chamber of Commerce in China.

    Until May 2014, Mr. Zarit was Minister for Commercial Affairs at the US Embassy in Beijing, overseeing the US Department of Commerce’s trade promotion and trade policy activities in its operations in Beijing, Chengdu, Guangzhou, Shanghai, and Shenyang. He retired with the rank of Career Minister.

    Prior to his posting to Beijing, Mr. Zarit was Deputy Assistant Secretary, International Operations, for the US Commercial Service, overseeing Commercial Sections in US Embassies and Consulates worldwide. He previously served as US Commercial Service’s Regional Director for East Asia/Pacific, Senior Commercial Officer at the US Embassy in Kuala Lumpur, Malaysia, Deputy Senior Commercial Officer at the US Embassy in Beijing, and Deputy Senior Commercial Officer at the American Institute in Taiwan.

    Before joining the US Commercial Service, Mr. Zarit was Economic and Commercial Program Officer for the New York-based National Committee on US-China Relations. Prior to that, he served as Marketing Manager/China for the California-based telecommunications firm Pacific Telesis International, preceded by his work as Project Manager for the high-tech marketing firm China Business Associates. Both positions were based in Beijing. Mr. Zarit also served as Mandarin Chinese Interpreter for the US State Department Language Services.

    He earned an MBA with Honors from the University of California, Berkeley, and a BA with Honors in Political Science from Miami University, Oxford, Ohio.

    Fisher Zhou
    Head of Healthcare Greater China of Corporate Finance
    CLSA

    Mr. Zhou is Head of Healthcare Greater China of Corporate Finance at CLSA. With over 10 years of experience in corporate finance in China and Hong Kong capital market, Mr. Zhou's prime focus is on medical services, medical devices and pharmaceutical, including origination, industry research and project execution across these sectors. He had led Kang Ning Hospital’s listing in HK in 2015 with proceeds of USD100m. He led or attended as a core member in deal of 3S Bio’s IPO, Universal Medical’s IPO, Lvye Pharm’s IPO.

    Mr. Zhou holds a Master in Finance from Guanghua School of Management, Peking University.

  3. Hotel

    2018 SUMMIT HOTEL

    We invite you to stay at the conference hotel, the Andaz Xintiandi Shanghai, in the vibrant Xintiandi district of Shanghai.

    Andaz Xintiandi Shanghai
    88 Songshan Road, Huangpu District
    Shanghai, China 200021
    Phone: +86 21 2310 1234

    The summit has negotiated special rates for attendees. Please email Hidy Fu at hidy.fu@lycheegroup.com to receive a hotel reservation form to book your accommodations.

  4. Visa Planning Tips

    Visa Planning Tips

    • Allow 4 weeks to complete the steps of the Chinese Visa application process
    • Check the expiration date of your passport and renew immediately if required
    • The Chinese Consulate requires your passport during the Visa application process.

    If you are traveling abroad prior to the Summit, you will need to factor your travel into the timing of your application.

    The length of time to secure a visa depends on the consulate at which the traveler is applying for the visa. And the traveler has to apply at the consulate which has jurisdiction for their state of residence. The consulate in San Francisco advises of a 4 business day turn-around, but they also have an expedited option. This assumes that all documents are in order. To gather all of the relevant documents, we usually estimate 1 week, so in theory the visa can be obtained in about 2 weeks.

    In addition to the Lychee Group China issued invitation letter, which is required by the Chinese Consulate, the traveler should also provide an original letter from their employer stating its financial support of the trip to the 2018 Healthcare Capital & Connections Summit.

    Invitation Letter

    Our conference logistics partner, Lychee Group China will issue the invitation letter required for attendees applying for a Chinese visa.  For Lychee to help issue the invitation letter, you need to:

    Lychee Group China will need 3 days to issue the invitation letter. Please submit the information for the Invitation Letter as soon as possible following Summit registration.

Founding Sponsors

Platinum Sponsors

Gold Sponsors

Strategic Sponsors

The presenters at Healthcare Capital & Connections Summit are independent third parties and are not affiliated with SVB Financial Group. See Terms of Use for more detail.

© 2018 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).